Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 54
- Registration Number
- NCT00655668
- Locations
- 🇫🇷
CHRU Hôpitaux de Brabois - Hématologie, Vandoeuvre Les Nancy, Rue Morvan Cedex, France
🇫🇷Hôpital Purpan, Toulouse, France
🇧🇪Institute Jules Bordet, Bruxelles, Belgium
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
- Conditions
- DS Stage III Multiple MyelomaDS Stage I Multiple MyelomaDS Stage II Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 525
- Registration Number
- NCT00644228
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Rose Medical Center, Denver, Colorado, United States
🇺🇸Kaiser Permanente-Richmond, Richmond, California, United States
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00642954
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 5
- Registration Number
- NCT00633945
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00633594
- Locations
- 🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States
🇺🇸RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00632359
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic LeukemiaCLLUntreatedFront-lineFirst-LineInitial Therapy
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2010-09-10
- Lead Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
- Target Recruit Count
- 80
- Registration Number
- NCT00628238
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 330
- Registration Number
- NCT00622336
- Locations
- 🇷🇺
Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod, Russian Federation
🇺🇦Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkov, Ukraine
🇺🇦Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
- Conditions
- Amyloidosis
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT00621400
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷CHRU d'Amiens, Amiens, France
🇫🇷CHRU de Lille, Lille, France
Proparacaine vs Placebo for Corneal Injuries
- Conditions
- Corneal Abrasions
- Interventions
- Drug: saline drops
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2008-02-22
- Lead Sponsor
- London Health Sciences Centre
- Target Recruit Count
- 43
- Registration Number
- NCT00620997
- Locations
- 🇨🇦
London Health Sciences Center, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.